. NEW DELHI: India remains among the countries bearing the highest burden of hepatitis-related deaths even as global efforts show progress, according to the WHO’s Global Hepatitis Report 2026, which warns that the world is off track to meet the 2030 elimination targets.The report flags viral hepatitis as a major public health threat, with over 1.3 million deaths globally in 2024—largely from hepatitis B and C, which together account for more than 95% of hepatitis-related deaths.Hepatitis B and C are viral infections that affect the liver and can remain silent for years before leading to cirrhosis and cancer.India figures prominently in the global burden. It is among ten countries that together account for nearly 69% of hepatitis B-related deaths worldwide and 58% of global hepatitis C deaths. India also has one of the largest hepatitis C burdens, ranking second after Pakistan; along with China, the three countries account for about 39% of global cases.According to WHO and ICMR estimates, India falls in the intermediate hepatitis B burden category, with a prevalence of around 2–4%, translating to nearly 40 million people living with chronic infection.“Despite vaccines and simple, affordable treatment, India continues to carry a high hepatitis burden due to gaps in vaccination coverage, unsafe exposures like needle sharing and razor reuse, and missed opportunities in screening — especially during pregnancy. The bigger problem is under-diagnosis, not treatment access. While prevalence has dropped sharply and free hepatitis C treatment has expanded, awareness, routine screening, and long-term treatment compliance remain weak. At the current pace, eliminating hepatitis C by 2030 looks unlikely, though it is achievable in the foreseeable future,” said Dr. Piyush Ranjan, Vice-chairperson, Institute of liver gastroenterology & pancreatico biliary science, Sir Gangaram Hospital.While there has been progress, it remains uneven. Globally, new hepatitis B infections have fallen by 32% since 2015 and hepatitis C deaths by 12%, but hepatitis B deaths have risen by 17%, pointing to gaps in diagnosis and treatment.An estimated 240 million people were living with chronic hepatitis B and 47 million with hepatitis C in 2024, yet treatment access remains limited—fewer than 5% of hepatitis B patients are on therapy and only about 20% of eligible hepatitis C patients have been treated.The report highlights that most hepatitis B infections occur in early childhood, often through mother-to-child transmission, while hepatitis C continues to spread through unsafe injections and blood exposure.Despite falling infection rates, progress is too slow to meet the 2030 target of sharply reducing new infections and deaths. The WHO has called for scaling up screening, treatment, vaccination and safer medical practices.About the AuthorAnuja JaiswalAnuja Jaiswal is a Senior Assistant Editor at The Times of India, with an impressive 18-year career in narrative journalism. She specializes in health and heritage reporting, expertly simplifying complex health information to make it engaging and understandable for readers. Her deep dives into heritage topics are well-researched, resulting in captivating narratives that resonate with her audience. Over the years, she has worked in Chandigarh, Chhattisgarh and West UP, gaining diverse on-ground experience that shapes her storytelling.Read MoreEnd of ArticleFollow Us On Social MediaVideosWhy the India-Bangladesh Border Fencing Delay Is Under SC and High Court Scrutiny: ExplainedDRDO & Indian Navy Successfully Conduct Maiden Salvo Launch Of NASM-SR Missile System12 Killed, Dozens Injured As Pickup Collides With SUV On Indore–Ahmedabad HighwayNYC Mayor Mamdani Says He’ll Urge King Charles To Return Kohinoor DiamondRaghav Chadha Fallout: Who Really Wins and Loses in Punjab?Mumbai–Pune Expressway’s ‘Missing Link’ Opens May 1: Faster Travel, Better Safety, No Extra Toll90-Year-Old Rejects Apology, Then Court Pushes ₹20 Crore Case to 2046Ganga Expressway Inaugurated: What ₹1,500 Toll Gets You on UP’s 594-km High-Speed Corridor | PM ModiUAE Quits OPEC In Big Oil Shake-Up: What It Means For India‘Siddaramaiah Ready To Step Down As Karnataka CM If Rahul Gandhi Asks’: Ex-Minister Rajanna123Photostories’Kyunki Saas Bhi Kabhi Bahu Thi 2′: Akashdeep Saigal’s casting as Rio sparks meme fest online – have a lookTaking painkillers in summer? The hidden kidney risk doctors warn aboutIndian bael or wood apple vs coconut water: Which is better for summer hydration?7 watering hacks every gardener should know5 things sons learn from their fathers that shape them for lifePrince William and Kate Middleton’s 15th wedding anniversary: From college crush to surviving cancer — 7 times they proved they were meant to be4 Zodiac signs who are done chasing wrong soulsWhat to plant in Australia this month: Complete seasonal gardening guide (and care tips)7 elite residential areas in Faridabad shaping real estate growthHow to grow banana tree at home (Simple step-by-step guide for beginners)123Hot PicksExit Poll Result 2026Bengal Election 2026Bengal ElectionPM ModiAjay Pal SharmaBengal Poll RecordHimanta Biswa SarmaTop TrendingPune Gas LeakBengaluru Wall CollapseMumbai L&T NewsDelhi NewsBengaluru FlyoverDelhi Mumbai ExpresswayMumbai Double MurderMumbai Police DeathBSE AP SSC Class 10th ResultIPL Orange Cap
NEW DELHI: India remains among the countries bearing the highest burden of hepatitis-related deaths even as global efforts show progress, according to the WHO’s Global Hepatitis Report 2026, which warns that the world is off track to meet the 2030 elimination targets.The report flags viral hepatitis as a major public health threat, with over 1.3 million deaths globally in 2024—largely from hepatitis B and C, which together account for more than 95% of hepatitis-related deaths.Hepatitis B and C are viral infections that affect the liver and can remain silent for years before leading to cirrhosis and cancer.India figures prominently in the global burden. It is among ten countries that together account for nearly 69% of hepatitis B-related deaths worldwide and 58% of global hepatitis C deaths. India also has one of the largest hepatitis C burdens, ranking second after Pakistan; along with China, the three countries account for about 39% of global cases.According to WHO and ICMR estimates, India falls in the intermediate hepatitis B burden category, with a prevalence of around 2–4%, translating to nearly 40 million people living with chronic infection.“Despite vaccines and simple, affordable treatment, India continues to carry a high hepatitis burden due to gaps in vaccination coverage, unsafe exposures like needle sharing and razor reuse, and missed opportunities in screening — especially during pregnancy. The bigger problem is under-diagnosis, not treatment access. While prevalence has dropped sharply and free hepatitis C treatment has expanded, awareness, routine screening, and long-term treatment compliance remain weak. At the current pace, eliminating hepatitis C by 2030 looks unlikely, though it is achievable in the foreseeable future,” said Dr. Piyush Ranjan, Vice-chairperson, Institute of liver gastroenterology & pancreatico biliary science, Sir Gangaram Hospital.While there has been progress, it remains uneven. Globally, new hepatitis B infections have fallen by 32% since 2015 and hepatitis C deaths by 12%, but hepatitis B deaths have risen by 17%, pointing to gaps in diagnosis and treatment.An estimated 240 million people were living with chronic hepatitis B and 47 million with hepatitis C in 2024, yet treatment access remains limited—fewer than 5% of hepatitis B patients are on therapy and only about 20% of eligible hepatitis C patients have been treated.The report highlights that most hepatitis B infections occur in early childhood, often through mother-to-child transmission, while hepatitis C continues to spread through unsafe injections and blood exposure.Despite falling infection rates, progress is too slow to meet the 2030 target of sharply reducing new infections and deaths. The WHO has called for scaling up screening, treatment, vaccination and safer medical practices.
